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Objective: Single-segment saphenous vein remains the optimal conduit for infrainguinal revascularization. In its absence,
prosthetic conduit may be used. Existing data regarding the signiﬁcance of anastomotic distal vein adjunct (DVA) usage
with prosthetic grafts are based on small series.
Methods: This is a retrospective cohort analysis derived from the regional Vascular StudyGroupofNewEngland aswell as the
Brigham andWomen’s hospital database. A total of 1018 infrainguinal prosthetic bypass grafts were captured in the dataset
from 73 surgeons at 15 participating institutions. Propensity scoring and 3:1 matching was performed to create similar
exposure groups for analysis. Outcome measures of interest included: primary patency, freedom from major adverse limb
events (MALEs), and amputation free survival at 1 year as a function of vein patch utilization. Time to event data were
comparedwith the log-rank test;multivariableCoxproportionalhazardmodelswereused toevaluate the adjusted association
between vein cuff usage and the primary end points. DVA was deﬁned as a vein patch, cuff, or boot in any conﬁguration.
Results: Of the 1018 bypass operations, 94 (9.2%) had a DVA whereas 924 (90.8%) did not (no DVA). After propensity
score matching, 88 DVAs (25%) and 264 no DVAs (75%) were analyzed. On univariate analysis of the matched cohort,
the DVA and no DVA groups were similar in terms of mean age (70.0 vs 69.0; P [ .55), male sex (58.0% vs 58.3%;
P > .99), and preoperative characteristics such as living at home (93.2% vs 94.3%; P[ .79) and independent ambulatory
status (72.7% vs 75.7%; P [ .64). The DVA and no DVA groups had similar rates of major comorbidities such as
hypertension chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, and dialysis dependence
(P > .05 for all). Likewise, they had similar rates of distal origin grafts (13.6% vs 12.5%; P[ .85), critical limb ischemia
indications (P[ .53), and prior arterial bypass (58% vs 47%; P[ .08). The DVA group had a higher rate of completion
angiogram performed (55.7% vs 37.5%; P [.002) and were more likely to be discharged on coumadin (53.4% vs 37.1%;
P[.01). By multivariable analysis, use of a distal DVA was protective against MALEs (hazard ratio, 0.36; 95% conﬁdence
interval, 0.14-0.90; P [ .03).
Conclusions: This contemporary multi-institutional propensity-matched study demonstrates that patients that receive
distal anastomotic vein adjuncts as part of infrainguinal prosthetic bypass operations in general have more extreme
comorbidities and more technically challenging operations based on level of target vessel and prior bypass attempts. After
propensity-matched analysis, the use of a DVA may protect against MALEs in prosthetic bypass surgery and should be
considered when feasible. (J Vasc Surg 2013;57:982-9.)Prosthetic conduit reconstructions for infrainguinal
occlusive disease are at times necessary despite the known
superiority of single segment great saphenous vein. Greater
than 20% of patients may have unusable superiority of single
segment great saphenous vein because of poor vein quality,
varicosities, or prior procurement for reconstruction in
other vascular beds, obliging the surgeon to consider
alternative conduit sources.1,2 The relative performance of
prosthetic conduit compared with alternative vein sources
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://dx.doi.org/10.1016/j.jvs.2012.10.098cryopreserved conduits have been the subject of multiple
studies.3-6 Despite their known limitations, however, pros-
thetic grafts remain an important option for lower extremity
bypass when more desirable choices are unavailable.
Data regarding adjunctive techniques to enhance the
performance of prosthetic grafts have mostly come from
small case series or trials, and the reported results have
been inconsistent.7-10 Some studies examining the utility
of anastomotic distal vein adjuncts (DVAs) have demon-
strated an association between DVA and superior graft
patency9 or improved limb salvage,7 whereas others have
found no difference in patency or limb salvage with anasto-
motic DVA usage in prosthetic bypasses.8
The purpose of this study was to evaluate the utilization
of DVAs for prosthetic lower extremity revascularizations
among academic and community vascular surgeons. An add-
itional aim was to determine if this technique improves the
performance of these disadvantaged conduits in a “real
world” cross-section of academic and community hospitals
from a regional quality improvement database.
METHODS
Patients and databases. This study was comprised of
a combined cohort derived from the Vascular Study Group
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Brigham and Women’s Hospital institutional database.
The VSGNE is a cooperative regional database started
in 2002 with the mission of quality improvement for
participating institutions, the details of which have been
previously described.11,12 Further information regarding
VSGNE participating institutions and surgeons can be
found at www.vsgne.org. The Brigham and Women’s
hospital (BWH) database is a prospectively maintained
registry of all lower extremity revascularization procedures
performed by all members of the division of vascular and
endovascular surgery.13,14
From the VSGNE database, any patient undergoing
an infrainguinal reconstruction for occlusive disease with
a prosthetic conduit from January 1, 2003 to June 30,
2010 was included. From the BWH database, any patient
that received a distal anastomotic vein adjunct to the
below-knee popliteal artery/tibioperoneal trunk from
January 1, 1995 to June 30, 2010 was included. As the Brig-
ham and Women’s Hospital joined the VSGNE database in
September 2011, there was no patient overlap between the
two databases.
Each patient was analyzed only once based on the ﬁrst
leg undergoing revascularization in the ﬁnal dataset to
avoid confounding related to “within-patient” depen-
dence.15 Inﬂow vessels included iliac, femoral, or popliteal
arteries. Outﬂow vessels included popliteal, tibial, or pedal
targets. Prosthetic conduits included those made of Dacron
or polytetraﬂuoroethylene (PTFE). Nonautogenous bio-
logic material and composite grafts of prosthetic and vein
were excluded from the ﬁnal model. Use of the distal
anastomotic vein adjunct is entered into the VSGNE data-
base as a binary yes/no variable, and more detailed infor-
mation on the conﬁguration of the adjunct constructed
(eg, vein patch, vein cuff, or boot, etc) is unavailable. Of
the 17 DVA patients from the BWH database, eight
were cuffs whereas nine were vein patches. In addition,
information regarding adjunctive outﬂow arteriovenous
ﬁstula creation is not routinely captured in the dataset.
Outcome measures. The main outcome measures of
interest were 1-year rates of primary patency, amputation-
free survival (AFS), and freedom from major adverse limb
events (MALEs).16 As recommended by the Society for
Vascular Surgery in their description of Objective Perfor-
mance Goals as study end points in critical limb ischemia
(CLI) studies,MALEwas deﬁned as the occurrence of one of
the following: ipsilateral major amputation, graft revision,
graft thrombectomy, or graft thrombolysis during the follow-
up interval.12,17 Patency rates were deﬁned by standard
criteria.18 Immediate postoperative outcomes were addi-
tionally evaluated and included in-hospital mortality, wound
infection, blood transfusion, myocardial infarction, and
discharge disposition.
Statistical analysis. Approval from the Brigham and
Women’s Hospital Institutional Review Board was ob-
tained. All analyses were performed using SAS v. 9.3
(SAS Institute, Cary, NC). Univariate analysis of categor-
ical variables was performed using the c2 or Fisher exacttest where appropriate. Continuous variables were assessed
for normality using the Shapiro-Wilk test and compared
using the Student t-test (two-tailed) or Wilcoxon rank sum
test depending on the normality of distribution. A P value
of <.05 was considered statistically signiﬁcant. Survival
curves were created using the Kaplan-Meier technique and
comparisons were made using the log-rank test.
Three separate multivariable Cox regression models
were constructed to determine whether DVA usage was
associated with the end points of primary patency, AFS,
and freedom from MALEs after adjustment for other
factors. These analyses were stratiﬁed into overall results as
well as “high risk grafts,” which were deﬁned as those
done for CLI indications with a distal anastomosis to
below-knee recipient vessels (below-knee popliteal, tibio-
peroneal trunk, tibials, and pedals). This was performed by
a backward elimination technique with independent factors
with an alpha level of <0.2 remaining in the ﬁnal model.
Possible confounders were considered and included in the
regression models as follows: age, sex, diabetes, smoking
history, hemodialysis, coronary artery disease, preoperative
independence level, preoperative ambulatory status, prior
operative bypass, ipsilateral CLI symptoms, preoperative sta-
tin use, preoperative antiplatelet use, urgency of case,
surgeon identiﬁcation, registry medical center, graft origin
level, distal anastomotic level, completion study, postopera-
tive complications such as myocardial infarction, wound
infection, and blood transfusion, discharge ambulatory
status, discharge disposition, and discharge antiplatelet, sta-
tin, and warfarin medication use. Regardless of signiﬁcance,
DVA was forced into each regression model as it was the
main exposure variable of interest.
Propensity analysis. Because of the inherent selection
bias related to “confounding by indication” in this type of
study, a matched propensity score analysis was performed
to create similar exposure groups for outcome analysis.
The initial dataset (n ¼ 1018) was evaluated, and patients
were scored based on their propensity to receive a DVA
based on other demographic, comorbid, and technical
factors (age, sex, race, diabetes, dialysis dependence, prior
bypass graft, surgical indication, graft inﬂow vessel, urgency
of case, and preoperative medications). Because of the
nonequivalent size of the initial exposure groups (DVA,
n ¼ 94; no DVA, n ¼ 914), matching was performed in
a 3:1 fashion (three no DVA patients to each one DVA
patient). After matching, our ﬁnal dataset for analysis
included 88 DVA and 264 no DVA patients. At an alpha
level of .05, this provides 67% power to detect a 10% differ-
ence in the DVA and no DVA proportions using the c2 test.
RESULTS
A total of 1018 patients that underwent an infraingui-
nal prosthetic graft reconstruction for occlusive disease in
the period of interest were identiﬁed. The procedures
were performed at 15 institutions by 73 different vascular
surgeons. Of these bypasses, 94 (9.2%) were performed
with a DVA whereas 924 (90.8%) were not. After propen-
sity score regression analysis and 3:1 matching based on
Table I. Baseline characteristics of patients with and without DVA
Total cohort Propensity-matched cohort
DVA (%) No DVA (%) P value DVA (%) No DVA (%) P value
N 94 (9.2) 924 (90.8) 88 (25.0) 264 (75.0)
Characteristics
Male sex 51 (54.3) 593 (64.2) .07 51 (58.0) 154 (58.3) >.99
White race 92 (97.9) 909 (98.4) .52 86 (97.7) 260 (98.5) .64
Living at home 88 (93.6) 884 (95.7) .43 82 (93.2) 249 (94.3) .79
Ambulates w/o assist 66 (70.2) 707 (76.5) .2 64 (72.7) 200 (75.7) .64
Age
Mean age [SD] 70.5 [10.8] 68.8 [11.1] .17 70 [10.9] 69.0 [11.2] .55
Median age [range] 71 [42-95] 69 [38-96] 69.5 [42-95] 69 [38-91]
Smoking (prior/current) 70 (74.5) 799 (86.8) .003 65 (73.9) 223 (84.5) .03
Comorbid conditions
Hypertension 83 (88.3) 806 (87.2) .87 79 (89.8) 234 (88.6) .85
COPD 29 (30.9) 316 (34.2) .57 27 (30.7) 96 (36.4) .37
Diabetes 55 (58.5) 451 (48.8) .08 50 (56.8) 140 (53.0) .62
CAD 49 (52.7) 395 (42.7) .08 45 (51.7) 116 (43.9) .22
Dialysis dependent 11 (11.7) 54 (5.8) .003 8 (9.1) 17 (6.4) .47
Pre-op medications
Antiplatelet 61 (64.9) 702 (76.0) .06 59 (67.0) 186 (70.4) .59
Statin 60 (63.8) 605 (65.5) .88 55 (62.5) 169 (64.0) >.99
Beta-blocker 82 (87.2) 731 (80.1) .1 77 (87.5) 197 (74.9) .02
Surgical indication .02 .53
Claudication 25 (26.6) 367 (39.7) 25 (31.2) 90 (34.1)
Rest pain 34 (36.2) 236 (25.5) 30 (34.1) 76 (28.8)
Tissue loss 35 (37.2) 321 (34.7) 33 (37.5) 98 (37.1)
Previous arterial bypass 55 (58.5) 252 (27.3) .014 51 (58.0) 124 (47.0) .08
Operative details
Urgency of case .005 .62
Elective 61 (64.9) 720 (77.9) 59 (67.0) 191 (72.3)
Urgent 31 (33.0) 174 (18.8) 27 (30.7) 67 (25.4)
Emergent 2 (2.1) 30 (3.2) 2 (2.3) 6 (2.3)
Graft origin .75 .85
Proximal (CFA/EIA) 80 (85.1) 796 (86.2) 76 (86.4) 231 (87.5)
Distal (SFA or below) 14 (14.9) 127 (13.8) 12 (13.6) 33 (12.5)
Graft recipient
Above-knee popliteal 20 (21.3) 531 (57.5) <.0001 20 (22.7) 162 (61.4) <.0001
Below-knee popliteal 55 (58.5) 252 (27.3) <.0001 53 (60.2) 78 (29.6) <.0001
Tibial vessel 18 (19.1) 104 (11.3) .03 15 (17.0) 22 (8.3) .02
Pedal vessel 1 (1.1) 37 (4.0) .24 0 (0) 1 (.38) >.99
Completion study
Any study 62 (66.0) 430 (46.5) .0003 56 (63.6) 111 (42.0) .0005
Angiogram 53 (56.4) 394 (42.6) .01 49 (55.7) 99 (37.5) .002
Duplex ultrasound 8 (8.5) 40 (4.3) .07 6 (6.8) 14 (5.3) .60
CAD, Coronary artery disease; CFA, common femoral artery; COPD, chronic obstructive pulmonary disease; EIA, external iliac artery; DM, diabetes mellitus;
DVA, distal vein adjunct; SD, standard deviation; SFA, superﬁcial femoral artery.
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and 264 (75.0%) no DVA patients. Table I displays the
baseline characteristics of the overall cohort as well as
the propensity-matched cohort. The baseline similarity
between the comparison groups improved dramatically
after propensity matching. The remainder of the outcome
analysis was performed on the matched cohort.
In the matched cohort, the DVA and no DVA groups
had similar baseline characteristics. The mean age was
similar for the DVA and no DVA groups (70.0 vs 69.0;
P ¼ .55). Likewise, both groups were predominantly male
(58.0% vs 58.3%; P > .99) and white (97.7% vs 98.5%;
P ¼ .64). In terms of baseline functional status, most of
the DVA and no DVA groups lived in a private home(93.2% vs 94.3%; P ¼ .79) and ambulated independently
prior to surgery (72.7% vs 75.7%; P ¼ .64). The two groups
were also well matched in terms of baseline comorbid condi-
tions such as hypertension, chronic obstructive pulmonary
disease, diabetes, coronary artery disease, dialysis depen-
dence, and smoking history (P > .05 for all). Likewise, the
two groups were similar in terms of CLI indications
(71.6% vs 65.9%; P ¼ .36), urgency of case (P ¼ .62), and
CFA graft origin (86.4% vs 87.5%; P ¼ .85). The DVA
and no DVA groups differed based on their level of distal
anastomosis with the DVA group having a higher propor-
tion of below-knee level of distal anastomosis (P < .0001).
DVA patients were also much more likely to undergo
completion imaging (63.6% vs 42.0%; P¼ .0005) (Table I).
Table II. Postoperative outcomes





In-hospital mortality 1 (1.1) 10 (3.8) .30
Wound infection 7 (7.9) 10 (3.8) .15
Blood transfusion 12 (15.0) 7 (3.0) .0001
Myocardial infarction 2 (2.3) 18 (6.8) .18
Data
Discharged on coumadin 47 (53.4) 98 (37.1) .009
Ambulation status
Independent 36 (40.9) 146 (55.3) .02
Disposition .003
Discharge to home 50 (57.5) 190 (74.8)
Discharge to nursing facility 37 (42.5) 64 (25.2)
DVA, Distal vein adjunct.
Fig 1. These unadjusted Kaplan-Meier curves demonstrate similar
1-year primary patency rates for the distal vein adjunct (DVA) and
no DVA patients overall (A) as well as for high-risk patients (B).
SE, Standard error.
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in-hospital mortality rates of 1.1% and 3.8%, respectively
(P ¼ .30; Table II). In addition, both groups had similarly
low rates of postoperative myocardial infarction (2.3% vs
6.8%; P ¼.18) and wound infection (7.9% vs 3.8%; P ¼
.15). The DVA group had a signiﬁcantly greater require-
ment for postoperative blood transfusion than did the no
DVA group (15.0% vs 3.0%; P ¼ .01) and of note, the
DVA group was more likely to be discharged on coumadin
(53.4% vs 37.1%; P ¼ .009). A smaller proportion of the
DVA patients were discharged directly to home postoper-
atively (57.5% vs 74.8%; P ¼ .003; Table II).
As shown in Fig 1, A, the DVA and no DVA groups
had similar overall rates of primary patency at 1 year
(73.8% 6 5.8% vs 70.6% 6 3.8%; P ¼ .94). Likewise, the
two groups had similar primary patency rates for the subset
of higher risk patients with CLI as their presenting indica-
tion and below-knee distal anastomoses (69.8% 6 7.9% vs
67.0% 6 7.4%; P ¼ .75; Fig 1, B).
The DVA and no DVA groups had similar rates of AFS
overall (70.6% 6 5.5% vs 75.8% 6 3.6%; P ¼ .83), as well
as for the highest risk grafts, (60.6% 6 7.5% vs 71.3% 6
7.6%; P ¼ .94; Fig 2, A and B).
DVA patients trended toward higher rates of freedom
from MALEs at 1 year compared with no DVA patients
overall (84.7% 6 5.5% vs 74.8% 6 3.6%; P ¼.33). When
limited to patients with CLI and with below-knee distal
anastomosis, the DVA group trended toward improved
freedom from MALEs compared with the no DVA group
(83.1% 6 5.9% vs 63.7% 6 8.0%; P ¼ .25; Fig 3, A and
B). The MALEs are demonstrated in Table III.
Of note, when the main outcome measures were
stratiﬁed by the medical center performing the procedure
(n ¼ 14), there was no difference for primary patency
(P ¼ .68), AFS (P ¼ .67) and freedom from MALEs
(P ¼ .73) across hospital designations (data not shown).
By multivariable Cox regression analysis, the use of
DVA was not independently associated with primary
patency overall, (hazard ratio [HR], 1.0; 95% CI, 0.54-
1.9), as well as for the high risk grafts (HR, 1.8; 95% CI,0.73-4.6). After adjustment for other factors, DVA usage
had a signiﬁcantly protective association with freedom
from MALEs overall (HR, 0.36; 95% CI, 0.14-0.90) and
a nonsigniﬁcant protective association for the high risk
group (HR, 0.23; 95% CI, 0.04-1.3). Usage of DVA
was not associated with AFS overall (HR, 0.79; 95% CI,
0.41-1.5) or for the high-risk patients (HR, 1.0; 95% CI,
0.44-2.5) (Table IV).DISCUSSION
Distal anastomotic vein adjuncts were ﬁrst described in
1979.19 They were later modiﬁed in the manner of a cuff in
198420 and again as a patch in 1992,21 and 2001.22,23
Fig 2. These unadjusted Kaplan-Meier curves demonstrate similar
1-year rates of amputation free survival (AFS) for all distal vein
adjunct (DVA) and no DVA patients (A) as well as those per-
formed on high-risk patients (B). SE, Standard error.
Fig 3. These unadjusted Kaplan-Meier curves demonstrate similar
1-year rates of freedom from major adverse limb events (MALEs)
for distal vein adjunct (DVA) and no DVA patients overall (A) as
well as those performed only on high-risk patients (B). SE, Stan-
dard error.
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between a prosthetic graft and native artery might be
beneﬁcial abound and include improved ﬂow dynamics,24
decreased mechanical injurious forces,25 an increased capac-
itance to allow for intimal hyperplastic overgrowth while
preserving a ﬂow lumen,7 constant ﬂow/washout of the
anastomosis,26 and lower ﬂow resistance at the distal target
than directly suturing a prosthetic graft to native artery.27
Despite these postulated beneﬁts, results assessing the
performance of vein adjuncts have been nonuniform and
even contradictory.
The main ﬁnding of this multi-institutional propensity-
matched study with 1-year follow-up was that infrainguinalprosthetic bypass grafts performed with DVAs are associ-
ated with lower rates of MALEs. Across the variety of
academic and community hospitals surveyed in the current
report, the highest risk groups (CLI indications with
below-knee distal anastomoses) demonstrated similar
patency and complication rates when compared with their
counterparts. Of note, a greater proportion of patients that
received aDVAunderwent completion imaging andwas dis-
charged on coumadin, supporting the commonly held view
that vascular surgeons are most likely to use a DVA when
concerned about the postoperative viability of a graft. While
Table III. MALEsa
DVA (%) No DVA (%)
N 88 264
Surgical revision/thrombectomy 15 40
Catheter based lysis 0 4
Major amputation 8 25
DVA, Distal vein adjunct; MALEs, major adverse limb events.
aSome patients had more than one event.
Table IV. Results: Cox proportional hazards for primary
patency, MALEs, and AFSa
HR 95% CIs P value
Lost primary patency Lower Upper
All patients
DVA 1.0 .54 1.9 .98
High-risk patientsb
DVA 1.8 .73 4.6 .19
MALEs
All patients
DVA .36 .14 .90 .03
High-risk patients
DVA .23 .04 1.3 .1
AFS
All patients
DVA .79 .41 1.5 .49
High-risk patients
DVA 1.0 .44 2.5 .91
AFS, Amputation-free survival; CIs, conﬁdence intervals; CLI, critical limb
ischemia; DVA, distal vein adjunct; HR, hazard ratio; MALEs, major
adverse limb events.
aBackward elimination regression model included age, sex, smoking history,
diabetes, dialysis dependence, coronary artery disease, prior bypass, indica-
tion for surgery, preoperative/postoperative medications (statin, beta
blocker, coumadin, antiplatelet), case urgency, preoperative ambulatory/
living status, graft origin level, graft recipient level, registry medical center,
surgeon identiﬁcation, postoperative complications, transfusion, and
completions study.
bIndicates CLI patients with distal anastomosis below the knee level
(popliteal, tibial, and pedal).
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has been debated,28,29 its institution typically reﬂects
a concern by the surgeon of certain high-risk characteristics
of the graft or patient.
Lundgren and colleagues recently published the Scan-
dinavian Miller Collar Study (SCAMICOS) in which 352
patients recruited between 1995 and 1998 and undergoing
below-knee popliteal and tibial PTFE bypass grafts
primarily for CLI (>90%) were randomized to a distal
vein collar versus no collar.8 Of relevance, participating
surgeons were free to perform the cuff technique of their
choosing and follow-up extended to 5 years. The SCAMI-
COS results were notable for similar patency and limb
salvage rates in both groups at both the below-knee popli-
teal as well as tibial level. However, while the randomized
design of the trial allowed for comparable baseline match-
ing of the two groups, the variability of surgical technique
(eg, inclusion of 5 mm grafts) and the lack of data on post-
operative anticoagulation management (eg, no informationon coumadin use provided) reduce the generalizability of
this study.
Contrasting results were reported from a second
contemporary randomized trial, this one performed in
the UK by the Joint Vascular Research Group on a noncon-
secutive cohort of 261 patients with initial 2-year10 and
later 3-year follow-up.9 All patients had a 6 mm graft,
and those randomized to the vein adjunct group had a stan-
dardized cuff created distally. The UK research group
found that a DVA was associated with improved patency
rates at the below-knee location, but was not at the
above-knee location. The observed patency beneﬁt did
not translate into improved limb salvage rates, which
were similar across all strata in the study. While their
cohorts were well-matched in terms of baseline characteris-
tics, details such as type and duration of postoperative anti-
coagulation were also lacking in this report. Similar to our
study, the UK trialists included claudicants as well as grafts
with above-knee (n ¼ 145) and below-knee distal anasto-
motic targets. While 1-year primary patency rates overall
compared favorably between the UK study and ours, the
predominance of above-knee vein cuffs (61%) included in
the UK study potentially limits the clinical applicability of
their ﬁndings given that most surgeons would not ﬁnd
this routinely necessary. As they did not stratify their results
by surgical indication, it is also unclear if the beneﬁt of the
cuff in the below-knee group was affected by the inclusion
of claudicants. In our study, those patients with CLI and
below-knee targets, the primary patency rates were similar
between the DVA and no DVA groups.
An additional proposed beneﬁt of DVA usage is that in
the event of graft thrombosis, the native outﬂow may be
preserved and serve to effectively lessen the ischemic insult
of graft occlusion.7,30 This protective beneﬁt could
conceivably translate into improved limb-salvage rates as
outﬂow vessels may be preserved from thrombotic
sequelae, preserving the patient’s preoperative baseline
condition. Much like the UK trialists ﬁnding, the current
work found that DVA usage was protective against MALEs
(HR, 0.36), lending support to this notion. Our ﬁndings
were in contrast to the single-institution report of Kreien-
berg et al comparing DVA with distal anastomotic arterio-
venous ﬁstula in 48 patients. Though poorly powered, they
noted that DVAs were associated with improved limb
salvage and may ultimately facilitate graft revision.7 Of
interest, four of 35 DVA patients in their series not
compliant with coumadin postoperatively all experienced
graft failure.
The use of “pre-cuffed” prosthetic grafts have the same
theoretic beneﬁts as autogenous vein cuffs and have been
shown to perform at the same level in at least one trial.31
Unfortunately, such PTFE graft conﬁgurations are not
distinctively coded in the VSGNE database, precluding
relevant subanalysis that would allow comment on their
performance in this study.
A principle limitation of an observational study evalu-
ating a surgical technique relates to the selection bias of
“confounding by indication.” Namely, the choice to use
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surgeon and will typically be dictated by factors that may
not be captured in a retrospective database analysis. In the
current work, factors such as arterial calciﬁcation, luminal
size, and quality as well as quality of runoff vessels is not
reliably captured. The goal of the propensity score is to
evaluate those factors that predicted the use of the distal
vein cuff and ﬁnd matching patients in the no DVA group
to allow for meaningful comparison. The current work
did ﬁnd adequate matching patients but this required
the sacriﬁce of some power by excluding >600 non-
matching patients. Ultimately, the loss of sample size
associated with matching the exposure groups (DVA vs
no DVA) limits this study’s ability to determine small
differences between exposure groups because of the lack
of power that may explain the lack of signiﬁcant differ-
ence in the univariate analysis of MALEs by the log-
rank test. As seen in Table I, the unmatched cohort had
vastly different baseline characteristics that would make
comparative analysis difﬁcult, which prompted the deci-
sion to proceed with the matched analysis despite the
diminished sample size. Despite propensity-matched anal-
ysis, there are persistent unmeasured confounders (vessel
quality, runoff, lumen diameter) that are not able to be
accounted for in a nonrandomized study design.
Other limitations in this study relate to its retrospective
cohort design derived from prospectively maintained data-
sets. The VSGNE relies on participating surgeon self-
reporting of cases with follow-up data abstracted by
nursing and other personnel at participating centers. The
potential for reporting bias has been previously described12
and is ideally limited to some degree by the voluntary
nature of the regional database participation through which
surgeons are less likely to report erroneous information.
While the VSGNE is a robust source of data, not all clinical
characteristics such as graft size and distal vein cuff conﬁg-
uration are captured leading to possible information bias.
An additional limitation was the inclusion of a sample of
nonconsecutive patients from the BWH vascular registry.
Unfortunately, vein cuff information is not routinely
captured from the BWH dataset and was available for only
a select cohort used for a different analysis. Although the
sampled time period overlapped with that of the VSGNE,
a dedicated institutional registry likely has more complete
follow-up information and by including only a self-selected
subset of such patients, selection bias is potentially intro-
duced. Lastly, follow-up information beyond 1 year is
currently unavailable with the VSGNE dataset, limiting
the utility of the current results to clinical decision-making.
In summary, the use of a distal vein cuff with prosthetic
lower extremity bypass appears to be used preferentially in
higher-risk patients (CLI patients, dialysis dependence,
and more distal anastomoses) as reﬂected in the initial total
cohort (Table I). Upon analysis of the propensity-matched
cohort, after adjustment for other factors, the selective use
of vein cuffs was protective against MALEs overall and
trended toward being protective for the high risk cohort
(CLI indications with below-knee distal anastomoses).In conclusion, when feasible, the use of a distal vein
cuff with a prosthetic bypass graft should be considered
(at all anastomotic levels) as it is associated with a lower
rate of MALEs.
AUTHOR CONTRIBUTIONS
Conception and design: JM, MM
Analysis and interpretation: JM, PG
Data collection: JM
Writing the article: JM
Critical revision of the article: JM, MM, AS, PG, MB
Final approval of the article: MM
Statistical analysis: JM, SS
Obtained funding: Not applicable
Overall responsibility: JM
REFERENCES
1. Chew DK, Owens CD, Belkin M, Donaldson MC, Whittemore AD,
Mannick JA, et al. Bypass in the absence of ipsilateral greater saphenous
vein: safety and superiority of the contralateral greater saphenous vein.
J Vasc Surg 2002;35:1085-92.
2. Taylor LM Jr, Edwards JM, Brant B, Phinney ES, Porter JM.
Autogenous reversed vein bypass for lower extremity ischemia in
patients with absent or inadequate greater saphenous vein. Am J Surg
1987;153:505-10.
3. Calligaro KD, Syrek JR, Dougherty MJ, Rua I, Raviola CA,
DeLaurentis DA. Use of arm and lesser saphenous vein compared with
prosthetic grafts for infrapopliteal arterial bypass: are they worth the
effort? J Vasc Surg 1997;26:919-24; discussion: 925-7.
4. Arvela E, SoderstromM, Alback A, Aho PS, Venermo M, Lepantalo M.
Arm vein conduit vs prosthetic graft in infrainguinal revascularization
for critical leg ischemia. J Vasc Surg 2010;52:616-23.
5. McPhee JT, Barshes NR, Ozaki CK, Nguyen LL, Belkin M. Optimal
conduit choice in the absence of single-segment great saphenous vein
for below-knee popliteal bypass. J Vasc Surg 2012;55:1008-14.
6. Bannazadeh M, Sarac TP, Bena J, Srivastava S, Ouriel K, Clair D.
Reoperative lower extremity revascularization with cadaver vein for
limb salvage. Ann Vasc Surg 2009;23:24-31.
7. Kreienberg PB, Darling RC III, Chang BB, Paty PS, Lloyd WE,
Shah DM. Adjunctive techniques to improve patency of distal pros-
thetic bypass grafts: polytetraﬂuoroethylene with remote arteriovenous
ﬁstulae versus vein cuffs. J Vasc Surg 2000;31:696-701.
8. SCAMICOS. PTFE bypass to below-knee arteries: distal vein collar or
not? A prospective randomised multicentre study. Eur J Vasc Endovasc
Surg 2010;39:747-54.
9. Grifﬁths GD, Nagy J, Black D, Stonebridge PA. Randomized clinical
trial of distal anastomotic interposition vein cuff in infrainguinal poly-
tetraﬂuoroethylene bypass grafting. Br J Surg 2004;91:560-2.
10. Stonebridge PA, Prescott RJ, Ruckley CV. Randomized trial
comparing infrainguinal polytetraﬂuoroethylene bypass grafting with
and without vein interposition cuff at the distal anastomosis. The Joint
Vascular Research Group. J Vasc Surg 1997;26:543-50.
11. Cronenwett JL, Likosky DS, Russell MT, Eldrup-Jorgensen J,
Stanley AC, Nolan BW. A regional registry for quality assurance and
improvement: the Vascular Study Group of Northern New England
(VSGNNE). J Vasc Surg 2007;46:1093-101; discussion: 1101-2.
12. Goodney PP, Schanzer A, Demartino RR, Nolan BW, Hevelone ND,
Conte MS, et al. Validation of the Society for Vascular Surgery’s
objective performance goals for critical limb ischemia in everyday
vascular surgery practice. J Vasc Surg 2011;54:100-8; e104.
13. Belkin M, Conte MS, Donaldson MC, Mannick JA, Whittemore AD.
Preferred strategies for secondary infrainguinal bypass: lessons learned
from 300 consecutive reoperations. J Vasc Surg 1995;21:282-293;
discussion: 293-5.
14. Belkin M, Donaldson MC, Whittemore AD. Composite autogenous
vein grafts. Semin Vasc Surg 1995;8:202-8.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 4 McPhee et al 98915. Marubini E, Braga M, Leite ML, Petroccione A, Pirotta N. “Within
patient”-dependent outcomes in graft occlusion after coronary artery
bypass. SINBA Group. Control Clin Trials 1993;14:296-307.
16. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested objective performance goals and clinical
trial design for evaluating catheter-based treatment of critical limb
ischemia. J Vasc Surg 2009;50:1462-73; e1461-63.
17. Conte MS. Understanding objective performance goals for critical limb
ischemia trials. Semin Vasc Surg 2010;23:129-37.
18. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
19. Siegman FA. Use of the venous cuff for graft anastomosis. Surg
Gynecol Obstet 1979;148:930.
20. Miller JH, Foreman RK, Ferguson L, Faris I. Interposition vein cuff for
anastomosis of prosthesis to small artery. Aust N Z J Surg 1984;54:283-5.
21. Taylor RS, Loh A, McFarland RJ, Cox M, Chester JF. Improved
technique for polytetraﬂuoroethylene bypass grafting: long-term results
using anastomotic vein patches. Br J Surg 1992;79:348-54.
22. Norberto JJ, Sidawy AN, Trad KS, Jones BA, Neville RF, Najjar SF,
et al. The protective effect of vein cuffed anastomoses is not mechanical
in origin. J Vasc Surg 1995;21:558-64; discussion: 564-6.
23. Neville RF, Tempesta B, Sidway AN. Tibial bypass for limb salvage
using polytetraﬂuoroethylene and a distal vein patch. J Vasc Surg
2001;33:266-71; discussion: 271-2.
24. Beard JD, Benveniste GL, Miller JH, Baird RN, Horrocks M. Hae-
modynamics of the interposition vein cuff. Br J Surg 1986;73:823-5.25. How TV, Rowe CS, Gilling-Smith GL, Harris PL. Interposition vein
cuff anastomosis alters wall shear stress distribution in the recipient
artery. J Vasc Surg 2000;31:1008-17.
26. Fisher RK, How TV, Carpenter T, Brennan JA, Harris PL. Optimising
miller cuff dimensions: the inﬂuence of geometry on anastomotic ﬂow
patterns. Eur J Vasc Endovasc Surg 2001;21:251-60.
27. Piorko D, Knez P, Nelson K, Schmitz-Rixen T. Compliance in anas-
tomoses with and without vein cuff interposition. Eur J Vasc Endovasc
Surg 2001;21:461-6.
28. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML,
Johnson BL, et al. The relative importance of graft surveillance and
warfarin therapy in infrainguinal prosthetic bypass failure. J Vasc Surg
2007;46:1160-6.
29. Pappas PJ, Hobson RW 2nd, Meyers MG, Jamil Z, Lee BC,
Silva MB Jr, et al. Patency of infrainguinal polytetraﬂuoroethylene
bypass grafts with distal interposition vein cuffs. Cardiovasc Surg
1998;6:19-26.
30. Raptis S, Miller JH. Inﬂuence of a vein cuff on polytetraﬂuoro-
ethylene grafts for primary femoropopliteal bypass. Br J Surg
1995;82:487-91.
31. Panneton JM, Hollier LH, Hofer JM. Multicenter randomized
prospective trial comparing a pre-cuffed polytetraﬂuoroethylene graft
to a vein cuffed polytetraﬂuoroethylene graft for infragenicular arterial
bypass. Ann Vasc Surg 2004;18:199-206.Submitted May 22, 2012; accepted Oct 22, 2012.
